2,6,9,13-tetraazatetradecane | 77500-19-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,6,9,13-tetraazatetradecane
• 英文别名: Z7TP8Q58FE；N-methyl-N'-[2-[3-(methylamino)propylamino]ethyl]propane-1,3-diamine
• CAS: 77500-19-7；999-22-4
• 化学式: C₁₀H₂₆N₄
• 分子量: 202.343
• InChiKey: DPOMNHXIZQXWGJ-UHFFFAOYSA-N

物化性质

• 沸点：
  106-109 °C(Press: 0.8 Torr)
• 密度：
  0.939±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  14
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  48.1
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  nickel(II) perchlorate hexahydrate 、 2,6,9,13-tetraazatetradecane 以 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  具有大环配体的金属配合物。XV。Ni 2+在DMSO和DMF中的开链和环状四氮杂配体与Ni的络合动力学†

  摘要：

  2,6,9,13-四氮杂十四烷（1），1,4,8、11-四氮杂环十四烷（2）和N，N'，N ''，N'-tetramethyl-1,4,8,11的络合动力学在DMSO和DMF中，采用停流技术研究了含Ni 2+的四氮杂环十四烷（3）。所述biomecular速率常数k大号的Ni（表2在两种溶剂）按照顺序1 ≳ 2 > 3的类似络合速率1和2它们的非质子化形式表明，对于开链和环状配体而言，具有相同的机理。通过与溶剂交换比较，络合的速率确定步骤是第一溶剂分子在外球络合物中​​的解离。3的较低反应性可能是由于空间效应。

  DOI：

  10.1002/hlca.19810640106

文献信息

• NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES
  申请人：Frydman Benjamin

  公开号：US20080194697A1

  公开（公告）日：2008-08-14

  Peptide conjugates in which cytostatic and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

  提供了肽共轭物，其中细胞生长抑制剂和细胞毒剂，如多胺类似物或萘醌，与多肽共轭，并被酶如前列腺特异性抗原（PSA）和半胱氨酸蛋白酶B识别和剪切，以及包含这些共轭物的组合物。还提供了使用这些共轭物治疗前列腺疾病的方法。
• Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
  申请人：Marton J. Laurence

  公开号：US20070232677A1

  公开（公告）日：2007-10-04

  This disclosure relates to methods of inhibiting vascular hyperplasia using polyamines, polyamine analogs, and conformationally restricted polyamine analogs, or a conjugate of a polyamine, polyamine analog, or conformationally restricted polyamine analog. Polyamines, polyamine analogs, conformationally restricted polyamine analogs, and conjugates thereof are useful in reducing stenosis and restenosis of blood vessels and grafts.

  本公开涉及使用多胺，多胺类似物和构象限制多胺类似物或多胺，多胺类似物或构象限制多胺类似物的共轭物来抑制血管增生的方法。多胺，多胺类似物，构象限制多胺类似物及其共轭物在减少血管和移植物的狭窄和再狭窄方面非常有用。
• Polyamine Analogs as Modulators of Cell Migration and Cell Motility
  申请人：Marton Laurence J.

  公开号：US20090143456A1

  公开（公告）日：2009-06-04

  This disclosure relates to methods of inhibiting cell motility or cell migration, and of treating diseases involving cell migration or cell motility, using polyamine analogs, such as conformationally restricted polyamine analogs. The diseases to be treated include immune disorders, inflammatory conditions, infection, abnormal immune responses, undesired angiogenesis, tumor cell metastasis or invasion, atherosclerosis, vascular graft occlusion, transplant rejection, other complications of transplants, glomerulonephritis, arthritis, inflammatory responses subsequent to stroke or ischemia, and asthma.

  本披露涉及使用聚胺类似物，如构象限制聚胺类似物，抑制细胞运动或细胞迁移的方法，以及治疗涉及细胞迁移或细胞运动的疾病。要治疗的疾病包括免疫障碍，炎症状况，感染，异常免疫反应，不良血管生成，肿瘤细胞转移或侵袭，动脉硬化，血管移植闭塞，移植排斥，移植其他并发症，肾小球肾炎，关节炎，中风或缺血后的炎症反应以及哮喘。
• Conformationally restricted polyamine analogs as disease therapies
  申请人：Frydman Benjamin

  公开号：US20070161692A1

  公开（公告）日：2007-07-12

  Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of delivering these analogs specifically to tumor cells by covalently attaching polyamine analogs to porphyrin compounds, along with novel polyamine-porphyrin covalent conjugates.
• PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
  申请人：McKearn John

  公开号：US20110112199A1

  公开（公告）日：2011-05-12

  Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.